Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > ASCO GU and AUA
View:
Post by DJDawg on Feb 08, 2023 11:47am

ASCO GU and AUA

Those of us who have been here a medium term or longer are very used to the game that happens with TLT.

Usual cycle
1. New data anticipated from a quarterly update.
2. Price builds.
3. New data released. Looks reasonable/good but presented in confusing way. Long holders stay put. Small group of others sell out of confusion or to create a swing down (again). Swing down works because most long holders have bought as much as need or can. So limited buyers to take advantage of swing down.
4. Price falls.
5. Repeat above 1-4.

Variations happen based on random things but that is most common pattern.

As such many can wonder if this will repeat with the upcoming data releases from ASCO and then the end Feb quarterly update.

It may happen.

However, there are a few differences this time.
- clinical data presented by main investigator/research vs TLT doing some confusing table or graph
- as such, more detail and likely more clear.
- when presenting at big meetings like ASCO and AUA there will be a lot of new viewers to hear about technology. Some will look up info on company and invest, even if small purchases. Urologists are very wealthy (in Canada, among the higher paid specialties) so they may invest some. There are no rules agains urologists investing in companies in their area.
- new buyers mean that a bit more balance between buyers and sellers when considering the steps 1-4 above.

So overall, there is reason to expect the next month to be different.

Or not. :)
Comment by Oilminerdeluxe on Feb 08, 2023 11:52am
Spot on!
Comment by ScienceFirst on Feb 08, 2023 12:33pm
FDA designation is what will bring higher valuation as it will be seen on the news wires that funds, brokers, analysts look at.  I don't expect much in terms of additional valuation regarding ASCO-GU and AUA.  But this will pay off over time, no doubt.
Comment by Tapps21 on Feb 08, 2023 12:44pm
Amazing post DJ and so true. Let's all hope.
Comment by Infinity on Feb 08, 2023 6:02pm
Well said DJ.  Agree with you 100%.  Dr, Kulkarni is a Veteran at this.  He knows the treatment better than anyone else, having been the lead investigator for several years... I expect some serious Media attention will follow and the results will speak for itself!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250